INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›health›Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
health

Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026

By Info60 World Desk•Summary of reporting by Businesswire•Sep 19, 2026•0 views•
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today presented new results from the Phase 3b study (NCT06973577) evaluating centanafadine in adults with attention-deficit/hyperactivity disorder (ADHD) and comorbid anxiety disorders at Psych Congress 2026 in New Orleans. Expanding on positive topline results shared in June, these analyses provide the most comprehensive view to date of centanaf
ONLY AVAILABLE IN PAID PLANS
Read Full Article

Share this story

Report an error

Up next

Related Stories

Amesite Announces New Sales Win Under NurseMagic® Minimum Enterprise Pricing Model

Globenewswire_fr

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Globenewswire_fr

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Globenewswire_fr

Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000

Globenewswire_fr

Re: Management of paracetamol (acetaminophen) toxicity

Bmj

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!